GenScript Biotech expects FY2025 adjusted net profit of USD 207.3-241.9 million

Reuters
03/10
<a href="https://laohu8.com/S/01548">GenScript</a> Biotech expects FY2025 adjusted net profit of USD 207.3-241.9 million

GenScript said adjusted net profit from continuing operations for FY2025 is expected at about USD 207.3 million to USD 241.9 million, versus about USD 59.8 million a year earlier. It expects license revenue of about USD 256.1 million to USD 298.8 million, compared with about USD 2.4 million in the prior period. The group expects a non-cash share of loss from Legend of about USD 304.4 million to USD 352.4 million and an impairment of its investment in Legend of about USD 378.2 million to USD 437.9 million. GenScript expects an FY2025 loss of about USD 505.8 million to USD 585.6 million, versus a profit of about USD 2.9 billion in the prior period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260310-12047626), on March 10, 2026, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10